Key result
Emerging pharmacological agents, including sacubitril/valsartan, SGLT2 inhibitors, firibastat, and aprocitentan, offer novel mechanisms of action to improve blood pressure control in hypertension.
Why the study?
Hypertension control remains poor worldwide despite its major contribution to the global burden of disease, creating an unmet clinical need for new drugs with novel mechanisms of action.
Design
Review
Authors
Loading...
May expand options for resistant hypertension; hypothesis-generating pending dedicated RCTs.
Emerging pharmacotherapies with novel mechanisms of action, such as firibastat, aprocitentan, and gut microbiota modification, offer potential new strategies for managing resistant and difficult-to-control hypertension.
Höcht et al. (2022) conducted a review in Hypertension. New antihypertensive agents was evaluated. Emerging pharmacological agents, including sacubitril/valsartan, SGLT2 inhibitors, firibastat, and aprocitentan, offer novel mechanisms of action to improve blood pressure control in hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: